Menu

Blog

Dec 15, 2016

TTFields Prolong Overall Survival in Glioblastoma

Posted by in categories: biotech/medical, neuroscience

Very promising for Giloblastoma patients.


Adding Tumor Treating Fields (TTFields) to maintenance temozolomide significantly prolongs both median and long-term survival.

Among patients with newly diagnosed glioblastoma multiforme, adding Tumor Treating Fields (TTFields) to maintenance temozolomide significantly prolongs both median and long-term survival, according to a study presented 21st Annual Scientific Meeting of the Society of Neuro-Oncology (SNO).

TTFields is a frequency-tuned, anti-mitotic, physical treatment modality delivered to the brain through a patient-operated, portable medical device called Optune. Results of a pre-specific successful interim analysis of the international, phase 3 trial (ClinicalTrials.gov Identifier: NCT00916409) comparing TTFields and temozolomide with temozolomide alone after radiotherapy and adjuvant temozolomide led to the approval of TTFields for the treatment of adult patients with glioblastoma.

Read more

Comments are closed.